BIKTARVY Dominates US HIV Market as HSBC Boosts Price Target

Gilead Sciences' BIKTARVY holds a significant share of the US HIV market, with approximately 52% of patients relying on this treatment. This dominance is not limited to existing users; BIKTARVY also accounts for over 70% of new starts in the US HIV treatment landscape.

The company has made recent progress with the approval of Bexlenvo, a weekly oral regimen developed in partnership with Merck. Although specifics on this development are scarce, it is set to be available next year.

Gilead Sciences also boasts robust patent protection for its treatments, which extend through 2036. However, the company's future plans may be affected by upcoming changes in US tax law, specifically the Inflation Reduction Act (IRA), which comes into effect in 2028.